In a recent prospective cohort study from the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN), changes in the ALT levels were significantly associated with fibrosis regression in NAFLD (30). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.